General Information of the Compound
| Compound ID |
CP0370713
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(NE)-N-[6-(3-morpholin-4-ylpropyl)-2-thieno[3,2-c]pyridin-6-ylchromen-4-ylidene]hydroxylamine
Show/Hide
|
||||||||||||||||||
| Synonyms |
DT-1386
DT-1687
MGluR4 PAM (neurological disease/psychiatric disorder), Domain Therapeutics
MGluR4 PAM (neurological disease/psychiatric disorder), Merck Serono
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C23H23N3O3S
|
||||||||||||||||||
| Molecular Weight |
421.522
|
||||||||||||||||||
| Canonical SMILES |
O\N=c1/cc(oc2ccc(CCCN3CCOCC3)cc12)-c1cc2sccc2cn1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C23H23N3O3S/c27-25-19-13-22(20-14-23-17(15-24-20)5-11-30-23)29-21-4-3-16(12-18(19)21)2-1-6-26-7-9-28-10-8-26/h3-5,11-15,27H,1-2,6-10H2/b25-19+
Show/Hide
|
||||||||||||||||||
| InChIKey |
ZTEDNASHAWNBKQ-NCELDCMTSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT02446, Metabotropic glutamate receptor 4
Protein ID: PT02199, Metabotropic glutamate receptor 4
Clinical Information about the Compound